Embryonic stem cells for severe heart failure: Why and how?

Journal of Cardiovascular Translational Research

Volumn 5, Issue 5, 2012, Pages 555-565

  Menasché, Philippe ^a,b,c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

Author keywords

Cardiac progenitors; Embryonic stem cells; Heart failure; Pluripotency

Indexed keywords

DNA METHYLTRANSFERASE 3B; LEFT RIGHT DETERMINATION FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; STAGE SPECIFIC EMBRYO ANTIGEN 1; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR;

ADVERSE OUTCOME; ANGIOGENESIS; APOPTOSIS; ARTICLE; CARCINOGENESIS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOPOIETIC MESENCHYMAL STEM CELL; CELL DIFFERENTIATION; CELL EXPANSION; CELL FATE; CELL FREE SYSTEM; CELL FUNCTION; CELL LINE; CELL POPULATION; CELL REGENERATION; CELL SURVIVAL; CELL TRANSFER; CELLULAR IMMUNITY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY BYPASS GRAFT; DEVELOPMENTAL STAGE; DISEASE CONTROL; DISEASE SEVERITY; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; ENGRAFTMENT; EXPERIMENTAL ANIMAL; FIBROBLAST; GRAFT VERSUS HOST REACTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE NECROSIS; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HEART TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INCIDENCE; INTERMETHOD COMPARISON; INTRACELLULAR SIGNALING; MEDICAL PROCEDURES; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR REPROGRAMMING; PARACRINE SIGNALING; PERICARDIUM; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PURIFICATION; RISK BENEFIT ANALYSIS; RISK FACTOR; STEM CELL; STEM CELL TRANSPLANTATION; TARGET ORGAN; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; VENTRICULOPLASTY; ANIMAL; CELL LINEAGE; CONVALESCENCE; HEART CONTRACTION; HEART MUSCLE; METABOLISM; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; REGENERATION; REGENERATIVE MEDICINE; REVIEW; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION;

ANIMALIA;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELL SURVIVAL; EMBRYONIC STEM CELLS; HEART FAILURE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; NECROSIS; PHENOTYPE; RECOVERY OF FUNCTION; REGENERATION; REGENERATIVE MEDICINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84874165949     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-012-9356-9     Document Type: Article

References (98)

1. Roger, V.; Go, A. S.; Lloyd-Jones, D. M.; Adams, R. J.; Berry, J. D.; Brown, T. M.; et al. (2011). Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation, 123, e18-e209.
2. Dickstein, K.; Cohen-Solal, A.; Filippatos, G.; McMurray, J. J.; Ponikowski, P.; Poole-Wilson, P. A.; et al. (2008). ESC guidelines for the diagnosis of acute and chronic heart failure 2008. European Heart Journal, 29, 2388-2442.
3. Jones, R. H.; Velazquez, E. J.; Michler, R. E.; Sopko, G.; Oh, J. K.; O'Connor, C. M.; et al. (2009). Coronary bypass surgery with or without surgical ventricular reconstruction. The New England Journal of Medicine, 360, 1705-1717.
4. Slaughter, M. S.; Meyer, A. L.; Birks, E. J. (2011). Destination therapy with left ventricular assist devices: patient selection and outcomes. Current Opinion in Cardiology, 26, 232-236.
5. Albouaini, K.; Egred, M.; Rao, A.; Alahmar, A.; Wright, D. J. (2008). Cardiac resynchronisation therapy: evidence based benefits and patient selection. European Journal of Internal Medicine, 19, 165-172.
6. Menasché, P. (2009). Cell-based therapy for heart disease: a clinically oriented perspective. Molecular Therapy, 17, 758-766.
7. Cho, H. J.; Lee, N.; Lee, J. Y.; Choi, Y. J.; Ii, M.; Wecker, A.; et al. (2007). Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. The Journal of Experimental Medicine, 204, 3257-3269.
8. Mirotsou, M.; Jayawardena, T. M.; Schmeckpeper, J.; Gnecchi, M.; Dzau, V. J. (2011). Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. Journal of Molecular and Cellular Cardiology, 50, 280-289.
9. Bollini, S.; Smart, N.; Riley, P. R. (2011). Resident cardiac progenitor cells: at the heart of regeneration. Journal of Molecular and Cellular Cardiology, 50, 296-303.
10. Pouly, J.; Bruneval, P.; Mandet, C.; Proksch, S.; Peyrard, S.; Amrein, C.; et al. (2008). Cardiac stem cells in the real world. The Journal of Thoracic and Cardiovascular Surgery, 135, 673-678.
11. Amir, G.; Ma, X.; Reddy, V. M.; Hanley, F. L.; Reinhartz, O.; Ramamoorthy, C.; et al. (2008). Dynamics of human myocardial progenitor cell populations in the neonatal period. The Annals of Thoracic Surgery, 86, 1311-1319.
12. Mishra, R.; Vijayan, K.; Colletti, E. J.; Harrington, D. A.; Matthiesen, T. S.; Simpson, D.; et al. (2011). Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation, 123, 364-373.
13. Bolli, R.; Chugh, A. R.; D'Amario, D.; Loughran, J. H.; Stoddard, M. F.; Ikram, S.; et al. (2011). Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet, 378, 1847-1857.
14. Gai, H.; Leung, E. L.; Costantino, P. D.; Aguila, J. R.; Nguyen, D. M.; Fink, L. M.; et al. (2009). Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts. Cell Biology International, 33, 1184-1193.
15. Pera, M. F. (2011). The dark side of induced pluripotency. Nature, 471, 46-47.
16. Zhao, T.; Zhang, Z. N.; Rong, Z.; Xu, Y. (2011). Immunogenicity of induced pluripotent stem cells. Nature, 474, 212-215.
17. Ieda, M.; Fu, J. D.; Delgado-Olguin, P.; Vedantham, V.; Hayashi, Y.; Bruneau, B. G.; et al. (2010). Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell, 42, 375-386.
18. Behfar, A.; Yamada, S.; Crespo-Diaz, R.; Nesbitt, J. J.; Rowe, L. A.; Perez-Terzic, C.; et al. (2010). Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. Journal of the American College of Cardiology, 56, 721-734.
19. Behfar, A.; Zingman, L. V.; Hodgson, D. M.; Rauzier, J. M.; Kane, G. C.; Terzic, A.; et al. (2002). Stem cell differentiation requires a paracrine pathway in the heart. The FASEB Journal, 16, 1558-1566.
20. Kehat, I.; Kenyagin-Karsenti, D.; Snir, M.; Segev, H.; Amit, M.; Gepstein, A.; et al. (2001). Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. The Journal of Clinical Investigation, 108, 407-414.
21. Sartiani, L.; Bettiol, E.; Stillitano, F.; Mugelli, A.; Cerbai, E.; Jaconi, M. E. (2007). Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach. Stem Cells, 25, 1136-1144.
22. Brito-Martins, M.; Harding, S. E.; Ali, N. N. (2008). Beta(1)- and beta(2)-adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: comparison with failing and non-failing adult human heart. British Journal of Pharmacology, 153, 751-759.
23. Mummery, C.; Ward-van Oostwaard, D.; Doevendans, P.; Spijker, R.; van den Brink, S.; Hassink, R.; et al. (2002). Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation, 107, 2733-2740.
24. Kofidis, T.; Lebl, D. R.; Swijnenburg, R. J.; Greeve, J. M.; Klima, U.; Robbins, R. C. (2006). Allopurinol/uricase and ibuprofen enhance engraftment of cardiomyocyte-enriched human embryonic stem cells and improve cardiac function following myocardial injury. European Journal of Cardio-Thoracic Surgery, 29, 50-55.
25. Laflamme, M.; Chen, K. Y.; Naumova, A. V.; Muskheli, V.; Fugate, J. A.; Dupras, S. K.; et al. (2007). Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nature Biotechnology, 25, 1015-1024.
26. Caspi, O.; Huber, I.; Kehat, I.; Xie, X.; Fu, J. D.; Drukker, M.; et al. (2007). Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. Journal of the American College of Cardiology, 50, 1884-1893.
27. Dai, W.; Field, L. J.; Rubart, M.; Reuter, S.; Hale, S. L.; Zweigerdt, R.; et al. (2007). Survival and maturation of human embryonic stem cell-derived cardiomyocytes in rat hearts. Journal of Molecular and Cellular Cardiology, 43, 504-516.
28. Leor, J.; Gerecht, S.; Cohen, S.; Miller, L.; Holbova, R.; Ziskind, A.; et al. (2007). Human embryonic stem cell transplantation to repair the infarcted myocardium. Heart, 93, 1278-1284.
29. Xie, C. Q.; Zhang, J.; Xiao, Y.; Zhang, L.; Mou, Y.; Liu, X.; et al. (2007). Transplantation of human undifferentiated embryonic stem cells into a myocardial infarction rat model. Stem Cells and Development, 16, 25-29.
30. Van Laake, L. W.; Passier, R. P.; Monshouwer-Kloots, J.; Verkleij, A. J.; Lips, D. J.; Freund, C.; et al. (2007). Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Research, 1, 9-24.
31. Tomescot, A.; Leschik, J.; Bellamy, V.; Dubois, G.; Messas, E.; Bruneval, P.; et al. (2007). Differentiation in vivo of cardiac committed human embryonic stem cells in post-myocardial infarcted rats. Stem Cells, 25, 2200-2205.
32. Cao, F.; Wagner, R. A.; Wilson, K. D.; Xie, X.; Fu, J. D.; Drukker, M.; et al. (2008). Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS One, 3, e3474.
33. Puymirat, E.; Geha, R.; Tomescot, A.; Bellamy, V.; Larghero, J.; Trinquart, L.; et al. (2009). Can mesenchymal stem cells induce tolerance to cotransplanted human embryonic stem cells? Molecular Therapy, 17, 176-182.
34. Fernandes, S.; Naumova, A. V.; Zhu, W. Z.; Laflamme, M. A.; Gold, J.; Murry, C. E. (2010). Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats. Journal of Molecular and Cellular Cardiology, 49, 941-949.
35. Habib, M.; Shapira-Schweitzer, K.; Caspi, O.; Gepstein, A.; Arbel, G.; Aronson, D.; et al. (2011). A combined cell therapy and in-situ tissue-engineering approach for myocardial repair. Biomaterials, 32, 7514-7523.
36. Yeghiazarians, Y.; Gaur, M.; Zhang, Y.; Sievers, R. E.; Ritner, C.; Prasad, M.; et al. (2011). Myocardial improvement with human embryonic stem cell-derived cardiomyocytes enriched by p38MAPK inhibition. Cytotherapy. doi: 10.3109/14653249.2011.623690.
37. Smits, A. M.; van Laake, L. W.; den Ouden, K.; Schreurs, C.; Szuhai, K.; van Echteld, C. J.; et al. (2009). Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium. Cardiovascular Research, 83, 527-535.
38. Song, H.; Yoon, C.; Kattman, S. J.; Dengler, J.; Massé, S.; Thavaratnam, T.; et al. (2010). Regenerative medicine special feature: interrogating functional integration between injected pluripotent stem cell-derived cells and surrogate cardiac tissue. Proc Natl Acad Sci USA, 107, 3329-3334.
39. Pillekamp, F.; Reppel, M.; Rubenchyk, O.; Pfannkuche, K.; Matzkies, M.; Bloch, W.; et al. (2007). Force measurements of human embryonic stem cell-derived cardiomyocytes in an in vitro transplantation model. Stem Cells, 25, 174-180.
40. Van Laake, L. W.; Passier, R.; den Ouden, K.; Schreurs, C.; Monshouwer-Kloots, J.; Ward-van Oostwaard, D.; et al. (2009). Improvement of mouse cardiac function by hESC-derived cardiomyocytes correlates with vascularity but not graft size. Stem Cell Research, 3, 106-112.
41. Singla, D. K.; McDonald, D. E. (2010). Factors released from embryonic stem cells inhibit apoptosis of H9c2 cells. American Journal of Physiology - Heart and Circulatory Physiology, 293, H1590-H1595.
42. Cristosomo, P. R.; Abarbanell, A. M.; Wang, M.; Lahm, T.; Wang, Y.; Meldrum, D. R. (2010). Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions. American Journal of Physiology - Heart and Circulatory Physiology, 95, H1726-H1735.
43. Blin, G.; Nury, D.; StefanovicS, N. T.; Guillevic, O.; Brinon, B.; Bellamy, V.; et al. (2010). A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in post-myocardial infarcted non-human primates. The Journal of Clinical Investigation, 120, 1125-1139.
44. Nakahara, M.; Saeki, K.; Nakamura, N.; Matsuyama, S.; Yogiashi, Y.; Yasuda, K.; et al. (2009). Human embryonic stem cells with maintenance under a feeder-free and recombinant cytokine-free condition. Cloning and Stem Cells, 11, 5-18.
45. Ilic, D.; Stephenson, E.; Wood, V.; Jacquet, L.; Stevenson, D.; Petrova, A.; et al. (2012). Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy, 14, 122-128.
46. Goldring, C. E.; Duffy, P. A.; Benvenisty, N.; Andrews, P. W.; Ben-David, U.; Eakins, R.; et al. (2011). Assessing the safety of stem cell therapeutics. Cell Stem Cell, 8, 618-628.
47. Hentze, H.; Soong, P. L.; Wang, S. T.; Phillips, B. W.; Putti, T. C.; Dunn, N. R. (2009). Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies. Stem Cell Research, 2, 198-210.
48. Kirouac, D. C.; Zandstra, P. W. (2008). The systematic production of cells for cell therapies. Cell Stem Cell, 3, 369-381.
49. Mayorga, M.; Finan, A.; Penn, M. (2009). Pre-transplantation specification of stem cells to cardiac lineage for regeneration of cardiac tissue. Stem Cell Reviews and Reports, 5, 51-60.
50. Pucéat, M. (2007). TGF-β in the differentiation of embryonic stem cells. Cardiovascular Research, 74, 256-261.
51. Kattman, S. J.; Huber, T. L.; Keller, G. M. (2006). Multipotent flk-1+ cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. Developmental Cell, 11, 723-732.
52. Yang, L.; Soonpaa, M. H.; Adler, E. D.; Roepke, T. K.; Kattman, S. J.; Kennedy, M.; et al. (2008). Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature, 453, 524-528.
53. Stefanovic, S.; Abboud, N.; Désilets, S.; Nury, D.; Cowan, C.; Pucéat, M. (2009). Interplay of Oct4 with Sox2 and Sox17: a molecular switch from stem cell pluripotency to specifying a cardiac fate. The Journal of Cell Biology, 186, 665-673.
54. Loh, K. M.; Lim, B. (2011). A precarious balance: pluripotency factors as lineage specifiers. Cell Stem Cell, 8, 363-369.
55. Hentze, H.; Graichen, R.; Colman, A. (2006). Cell therapy and the safety of embryonic stem cell-derived grafts. Trends in Biotechnology, 25, 24-32.
56. Kiuru, M.; Boyer, J.; O'Connor, T. P.; Crystal, R. G. (2009). Genetic control of wayward pluripotent stem cells and their progeny after transplantation. Cell Stem Cell, 4, 289-300.
57. Behfar, A.; Hodgson, D. M.; Zingman, L. V.; Perez-Terzic, C.; Yamada, S.; Kane, G. C.; et al. (2005). Administration of allogenic stem cells dosed to secure cardiogenesis and sustained infarct repair. Annals of the New York Academy of Sciences, 1049, 189-198.
58. Prokhorova, T. A.; Harkness, L. M.; Frandsen, U.; Ditzel, N.; Schrøder, H. D.; Burns, J. S.; et al. (2008). Teratoma formation by human embryonic stem cells is site-dependent and enhanced by the presence of Matrigel. Stem Cells and Development, 18, 47-54.
59. Calderon, D.; Planat-Benard, V.; Bellamy, V.; Vanneaux, V.; Khun, C.; Peyrard, S.; et al. (2011). Immune response to human embryonic stem cell-derived cardiac progenitors and adipose-derived stromal cells. Journal of Cellular and Molecular Medicine. doi: 10.1111/j.1582-4934.2011.01435.
60. Grinnemo, K. H.; Kumagai-Braesch, M.; Mansson-Broberg, A.; Månsson-Broberg, A.; Skottman, H.; Hao, X.; et al. (2006). Human embryonic stem cells are immunogenic in allogeneic and xenogeneic settings. Reproductive Biomedicine Online, 13, 712-724.
61. Swijnenburg, R. J.; Schrepner, S.; Govaert, J.; Cao, F.; Ransohoff, K.; Sheikh, A. Y.; et al. (2008). Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proceedings of the National Academy of Sciences of the United State of America, 105, 12991-12996.
62. Heydendael, V. M.; Spuls, P. I.; Ten Berge, I. J.; Opmeer, B. C.; Bos, J. D.; de Rie, M. A. (2002). Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. British Journal of Dermatology, 147, 22-129.
63. Lindvall, O.; Kokaia, Z. (2009). Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Trends in Pharmacological Sciences, 30, 260-267.
64. Taylor, C. J.; Bolton, E. M.; Pocock, S.; Sharples, L. D.; Pedersen, R. A.; Bradley, A. (2005). Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet, 366, 2019-2025.
65. Fraga, A. M.; Sukoyan, M.; Rajan, P.; de Almeida, P.; Ferreira Braga, D.; Iaconelli, A.; et al. (2011). Establishment of a Brazilian line of human embryonic stem cells in defined medium: implications for cell therapy in an ethnically diverse population. Cell Transplantation, 20, 431-440.
66. Fairchild, P. (2010). The challenge of immunogenicity in the quest for induced pluripotency. Nature Reviews Immunology, 10, 868-875.
67. Scandling, J. D.; Busque, S.; Shizuru, J. A.; Engleman, E. G.; Strober, S. (2011). Induced immune tolerance for kidney transplantation. New England Journal of Medicine, 365, 1359-1360.
68. Chidgey, A. P.; Layton, D.; Trounson, A.; Boyd, R. (2008). Tolerance strategies for stem-cell-based therapies. Nature, 453, 330-337.
69. Chatenoud, L. (2003). CD3-specific antibody-induced active tolerance: from bench to bedside. Nature Reviews Immunology, 3, 123-132.
70. Keymeulen, B.; Walter, M.; Mathieu, C.; Kaufman, L.; Gorus, F.; Hilbrands, R.; et al. (2010). Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia, 53, 614-623.
71. Fukushima, S.; Varela-Carver, A.; Coppen, S. R.; Yamahara, K.; Felkin, L. E.; Lee, J.; et al. (2007). Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation, 115, 2254-2261.
72. Zvibel, I.; Smets, F.; Soriano, H. (2002). Anoikis: roadblock to cell transplantation? Cell Transplantation, 11, 621-630.
73. Robey, T. E.; Saiget, M. K.; Reinecke, H.; Murry, C. E. (2008). Systems approaches to preventing transplanted cell death in cardiac repair. Journal of Molecular and Cellular Cardiology, 45, 567-581.
74. Stevens, K. R.; Kreutziger, K. L.; Dupras, S. K.; Korte, F. S.; Regnier, M.; Muskheli, V.; et al. (2009). Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proceedings of the National Academy of Sciences of the United States of America, 106, 16568-16573.
75. Matsuura, K.; Honda, A.; Nagai, T.; Fukushima, N.; Iwanaga, K.; Tokunaga, M.; et al. (2009). Transplantation of cardiac progenitor cells ameliorates cardiac dysfunction after myocardial infarction in mice. The Journal of Clinical Investigation, 119, 2204-2217.
76. Zakharova, L.; Mastroeni, D.; Mutlu, N.; Molina, M.; Goldman, S.; Diethrich, E.; et al. (2010). Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function. Cardiovascular Research, 87, 40-49.
77. Matsuura, K.; Masuda, S.; Haraguchi, Y.; Yasuda, N.; Shimizu, T.; Hagiwara, N.; et al. (2011). Creation of mouse embryonic stem cell-derived cardiac cell sheets. Biomaterials, 32, 7355-7362.
78. Hamdi, H.; Furuta, A.; Bellamy, V.; Bel, A.; Puymirat, E.; Peyrard, S.; et al. (2009). Cell delivery: intramyocardial injections or epicardial deposition? A head-to-head comparison. The Annals of Thoracic Surgery, 87, 1196-1203.
79. Xiong, Q.; Hill, K. L.; Li, Q.; Suntharalingam, P.; Mansoor, A.; Wang, X.; et al. (2011). A fibrin patch-based enhanced delivery of human embryonic stem cell-derived vascular cell transplantation in a porcine model of postinfarction left ventricular remodeling. Stem Cells, 29, 367-375.
80. Baharvand, H.; Azarnia, M.; Parivar, K.; Ashtiani, S. K. (2005). The effect of extracellular matrix on embryonic stem cell-derived cardiomyocytes. Journal of Molecular and Cellular Cardiology, 38, 495-503.
81. Duan, Y.; Liu, Z.; O'Neill, J.; Wan, L. Q.; Freytes, D. O.; Vunjak-Novakovic, G. (2011). Hybrid gel composed of native heart matrix and collagen induces cardiac differentiation of human embryonic stem cells without supplemental growth factors. Journal of Cardiovascular Translational Research, 5, 605-615.
82. Lu, W. N.; Lü, S. H. L.; Wang, H. B.; Li, D. X.; Duan, C. M.; Liu, Z. Q.; et al. (2009). Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel. Tissue Engineering. Part A, 15, 1437-1447.
83. Yu, J.; Du, K. T.; Fang, Q.; Gu, Y.; Mihardja, S. S.; Sievers, R. E.; et al. (2010). The use of human mesenchymal stem cells encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in the rat. Biomaterials, 27, 7012-7020.
84. Kraehenbuehl, T. P.; Zammaretti, P.; Van der Vlies, A. J.; Schoenmakers, R. G.; Lutolf, M. P.; Jaconi, M. E.; et al. (2008). Three-dimensional extracellular matrix-directed cardioprogenitor differentiation: systematic modulation of a synthetic cell-responsive PEG-hydrogel. Biomaterials, 29, 2757-2766.
85. Wang, H.; Liu, Z.; Li, D.; Guo, X.; Kasper, F. K.; Duan, C.; et al. (2011). Injectable biodegradable hydrogels for embryonic stem cell transplantation: improved cardiac remodeling and function of myocardial infarction. Cellular and Molecular Medicine. doi: 10.1111/j.1582-4934.2011. 01409.
86. Singelyn, J. M.; DeQuach, J. A.; Seif-Naraghi, S. B.; Littlefield, R. B.; Schup-Magoffin, P. J.; Christman, K. L. (2009). Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Biomaterials, 30, 5409-5416.
87. Aguado, B. A.; Mulyasasmita, W.; Su, J.; Lampe, K. L.; Heilshorn, S. C. (2011). Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Engineering. Part A. doi: 10.1089/ten.tea.2011.0391.
88. Nguyen, P. K.; Lan, F.; Wang, Y.; Wu, J. C. (2011). Guiding the clinical translation of cardiac stem cell therapy. Circulation Research, 109, 962-979.
89. Sekine, H.; Shimizu, T.; Hobo, K.; Sekiya, S.; Yang, J.; Yamato, M.; et al. (2008). Endothelial cell coculture within tissue-engineered cardiomyocyte sheets enhances neovascularization and improves cardiac function of ischemic hearts. Circulation, 118, S145-S152.
90. Winter, E. M.; van Oorschot, H. B.; van der Graaf, L. M.; Doevendans, P. A.; Poelmann, R. E.; Atsma, D. E.; et al. (2009). A new direction for cardiac regeneration therapy. Application of synergistically acting epicardium-derived cells and cardiomyocyte progenitor cells. Circulation of Heart Failure, 2, 643-653.
91. Sekine, H.; Shimizu, T.; Dobashi, I.; Matsuura, K.; Hagiwara, N.; Takahashi, M.; et al. (2011). Cardiac cell sheet transplantation improves damaged heart function via superior cell survival in comparison with dissociated cell injection. Tissue Engineering. Part A, 17, 2973-2980.
92. Hamdi, H.; Planat-Benard, V.; Bel, A.; Puymirat, E.; Geha, R.; Pidial, L.; et al. (2011). Epicardial adipose stem cell sheets results in greater post-infarction survival than intramyocardial injections. Cardiovascular Research, 91, 483-491.
93. Guilak, F.; Cohen, D. M.; Estes, B. T.; Gimble, J. M.; Liedtke, W.; Chen, C. S. (2009). Control of stem cell fate by physical interactions with the extracellular matrix. Cell Stem Cell, 5, 17-26.
94. Zarembinski, T. I.; Tew, W. P.; Atzet, S. K. The use of a hydrogel matrix as a cellular delivery vehicle in future cell-based therapies: biological and non-biological considerations. In: D. Eberli (Ed.), Regenerative medicine and tissue engineering - cells and biomaterials. ISBN: 978-953-307-663-8, InTech available from: hhow/title/ttp://www.intechopen.com/articles/show/title/ the-use-of-a-hydrogel- matrix-as-a-cellular-delivery-vehicle-in-future-cell- based therapies-biologica.
95. Zoldan, J.; Karagiannis, E.; Lee, C. Y.; Anderson, D. G.; Langer, R.; Levenberg, S. (2011). The influence of scaffold elasticity on germ layer specification of human embryonic stem cells. Biomaterials, 32, 9612-9621.
96. Miyagi, Y.; Chiu, L. L.; Cimini, M.; Weisel, R. D.; Radisic, M.; Li, R. K. (2011). Biodegradable collagen patch with covalently immobilized VEGF for myocardial repair. Biomaterials, 32, 1280-1290.
97. Amsalem, Y.; Mardor, Y.; Feinberg, M. S.; Landa, N.; Miller, L.; Daniels, D.; et al. (2007). Iron-oxide labeling and outcome of transplanted mesenchymal stem cells in the infarcted myocardium. Circulation, 116(11 Suppl), I38-I145.
98. Yaghoubi, S. S.; Jensen, M. C.; Satyamurthy, N.; Budhiraja, S.; Paik, D.; Czernin, J.; et al. (2009). Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nature Clinical Practice Oncology, 6, 53-58.